(0.03%) 5 518.50 points
(0.13%) 39 895 points
(0.06%) 19 763 points
(0.01%) $81.64
(0.50%) $2.83
(-0.26%) $2 338.30
(0.17%) $29.58
(0.64%) $1 008.20
(0.13%) $0.933
(-0.04%) $10.53
(0.03%) $0.788
(-0.85%) $87.25
0.70% $ 14.33
Live Chart Being Loaded With Signals
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States...
Stats | |
---|---|
Dzisiejszy wolumen | 635 658 |
Średni wolumen | 1.55M |
Kapitalizacja rynkowa | 746.89M |
EPS | $-0.570 ( Q1 | 2024-05-06 ) |
Następna data zysków | ( $-0.550 ) 2024-08-05 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-5.92 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0240 (0.17%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-27 | Kaye Edward M. Md | Buy | 159 000 | Employee Stock Option (Right to Buy) |
2024-03-27 | Kaye Edward M. Md | Buy | 105 000 | Restricted Stock Units |
2024-03-27 | Nash Huw M. | Buy | 60 000 | Employee Stock Option (Right to Buy) |
2024-03-27 | Nash Huw M. | Buy | 40 000 | Restricted Stock Units |
2024-03-27 | Ticho Barry | Buy | 60 000 | Employee Stock Option (Right to Buy) |
INSIDER POWER |
---|
-49.77 |
Last 98 transactions |
Buy: 1 784 499 | Sell: 5 127 514 |
Wolumen Korelacja
Stoke Therapeutics Inc Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
FUSN | 0.953 |
CDXC | 0.938 |
VTVT | 0.936 |
ACTG | 0.936 |
RAIL | 0.935 |
OCGN | 0.93 |
NWLI | 0.93 |
KNTK | 0.93 |
ATOS | 0.928 |
PESI | 0.927 |
10 Najbardziej negatywne korelacje | |
---|---|
NLSP | -0.943 |
BTTX | -0.921 |
ADBE | -0.913 |
TACT | -0.91 |
ISPC | -0.909 |
HNRG | -0.909 |
FRHC | -0.905 |
BSBK | -0.905 |
MVIS | -0.903 |
LUNA | -0.902 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Stoke Therapeutics Inc Korelacja - Waluta/Towar
Stoke Therapeutics Inc Finanse
Annual | 2023 |
Przychody: | $8.78M |
Zysk brutto: | $4.05M (46.14 %) |
EPS: | $-2.38 |
FY | 2023 |
Przychody: | $8.78M |
Zysk brutto: | $4.05M (46.14 %) |
EPS: | $-2.38 |
FY | 2022 |
Przychody: | $12.41M |
Zysk brutto: | $8.87M (71.50 %) |
EPS: | $-2.39 |
FY | 2021 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-2.33 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Stoke Therapeutics Inc
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej